NC Registry

NUT midline carcinoma (NMC) is a rare and aggressive human cancer defined by rearrangements of the gene NUT.

The majority of NMCs cases are attributed to the fusion of the NUT gene to either BRD4 or BRD3, creating chimeric genes that encode BRD-NUT fusion proteins. In the remaining cases, NUT is fused to an unknown partner gene; these tumors are termed NUT-variant. Our NMC Registry team collects clinical data regarding response to various treatments, which may facilitate future therapeutic strategies.

11/17/2023

There is a clinical trial combining a BET inhibitor, ZEN003694, with CDK inhibitor, abemaciclib, for adult and pediatric patients (Age >= 12) with NUT Carcinoma. Additional information about this trial can be found at the following link:
https://clinicaltrials.gov/study/NCT05372640

11/17/2023

There is a clinical trial utilizing a dual BET and CBP/p300 inhibitor in adult patients with targeted advanced solid tumors (including NUT Carcinoma). Additional information about this trial can be found at the following link:
https://clinicaltrials.gov/study/NCT05488548?term=NCT05488548&rank=1

Address

New Research Building Rm 630G, 77 Avenue Louis Pasteur
Boston, MA
02115

Telephone

(617) 525-4415

Website

http://nc-registry.org/

Alerts

Be the first to know and let us send you an email when NC Registry posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Want your practice to be the top-listed Clinic in Boston?

11/17/2023

11/17/2023

Address

Telephone

Website

Alerts

Shortcuts

Share